## Recommended Doses for Currently Licensed Hepatitis B Vaccines

PATIENT'S AGE	RECOMBIVAX HB® (Merck & Co.) FORMULATION¹			ENGERIX-B® (GlaxoSmithKline) FORMULATION		
	PEDIATRIC/ ADOLESCENT 5 mcg/0.5 ml	ADULT 10 mcg/1.0 ml	DIALYSIS 40 mcg/1.0 ml	PEDIATRIC/ ADOLESCENT 10 mcg/0.5 ml	ADULT 20 mcg/1.0 ml	DIALYSIS 40 mcg/2.0 ml
BIRTH <sup>2</sup> – 10 YEARS	3-dose series 5.0 mcg/ 0.5 ml	N/A	N/A	3-dose series 10 mcg/ 0.5 ml	N/A	N/A
11-19 YEARS	3-dose series 5.0 mcg/ 0.5 ml	3-dose series 5.0 mcg/ 0.5 ml	N/A	3-dose series 10 mcg/ 0.5 ml	3-dose series 20 mcg/ 1.0 ml <sup>3</sup>	N/A
11-15 YEARS ONLY <sup>4</sup>	3-dose series 5.0 mcg/ 0.5 ml 2-dose series 2 X 5.0 mcg/ 0.5 ml	2-dose series 10.0 mcg/ 1.0 ml	N/A	N/A	N/A	N/A
ADULT (20 years and older)	N/A	3-dose series 10 mcg/ 1.0 ml	3-dose series 40 mcg/1.0 ml (Dialysis Formulation)	N/A	3-dose series 20 mcg/ 1.0 ml	4-dose series 40mcg/ 2.0 ml <sup>5</sup>

N/A = Vaccine not approved for use in this age group

Please note:

- 1) Except where alternate dosing schedules are recommended, there should be at least one month between the first and second doses of hepatitis B; the third dose should be administered at least 4 months after the first dose and at least 2 months after the second dose; in infants, the third dose should <u>never</u> be given before 6 months of age. Using a 3-dose series, there are no maximum intervals.
- 2) The immune response using 1 or 2 doses of a vaccine produced by one manufacturer followed by 1 or more subsequent doses from a different manufacturer has been demonstrated to be comparable to a full course of immunization with a single product.

## Remember to always check the package insert prior to administration

For Merck hepatitis B vaccine product only, if the suggested formula is not available, the appropriate dosage can be achieved from another formulation provided that the total volume of vaccine administered does not exceed 1.0 ml. However, the Dialysis Formulation may only be used for adult peridialysis/dialysis patients.

<sup>&</sup>lt;sup>2</sup> Infants born to HBsAg-positive women should also receive hepatitis B immune globulin (HBIG) within 12 hours of birth.

Engerix-B® Adult formulation should only be used if Engerix-B® Pediatric formulation, Recombivax HB® Pediatric/Adolescent formulation and Recombivax HB® Adult formulation are not available. An alternate dosing schedule for Engerix-B® is 0, 1, 2, 12 months. When the alternate schedule is used for adolescents, the 20 mcg/1.0 ml dose should be used.

<sup>&</sup>lt;sup>4</sup> Adolescents (11 to 15 years of age <u>only</u>) may receive either regimen: 1) the 3-dose series of 5 mcg/0.5 ml Recombivax HB® Pediatric/Adolescent formulation given according to the usual schedule; or 2) the 2-dose series of <u>either</u> the 10 mcg/1.0 ml Recombivax HB® Adult formulation <u>or</u> two 5.0 mcg/0.5 ml doses of Recombivax HB® Pediatric/Adolescent formulation given as a single 1.0 ml injection. For the 2-dose series, give the 1st dose at month 0, and the 2nd dose 4-6 months later; <u>both</u> doses must be administered while the adolescent is 11-15 years of age.

<sup>&</sup>lt;sup>5</sup> Two 20 mcg doses given as two 1.0 ml injections or one 2.0 ml injection at 0, 1, 2, 6 months.